Literature DB >> 34552755

Cytokine storms, evolution and COVID-19.

Joe Alcock1, Alix Masters2.   

Abstract

Since the identification of severe illness caused by the novel coronavirus SARS-CoV-2, the role of the host immune system in causing disease has attracted widespread attention, along with intense interest in medical interventions that target the host immune response. A wide variety of agents have been proposed to treat a cytokine storm in coronavirus disease 2019 (COVID-19), but so far, only one class of medications, corticosteroids, has proved useful. In recent decades, experimental therapies for cytokine storms have been tried and mostly failed to help patients with severe sepsis and other infections. We summarize this history in order to frame expectations for novel interventions in COVID-19 and to bring an evolutionary medicine perspective to the concept of cytokine storms and their treatment.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health.

Entities:  

Keywords:  Covid-19; SARS-CoV-2; corticosteroids; cytokine storm; immunity

Year:  2021        PMID: 34552755      PMCID: PMC7928963          DOI: 10.1093/emph/eoab005

Source DB:  PubMed          Journal:  Evol Med Public Health        ISSN: 2050-6201


  80 in total

1.  Thymic involution.

Authors:  P W Turke
Journal:  Immunol Today       Date:  1997-08

2.  An evolutionary life-history framework for understanding sex differences in human mortality rates.

Authors:  Daniel J Kruger; Randolph M Nesse
Journal:  Hum Nat       Date:  2006-03

3.  High-dose corticosteroids in patients with the adult respiratory distress syndrome.

Authors:  G R Bernard; J M Luce; C L Sprung; J E Rinaldo; R M Tate; W J Sibbald; K Kariman; S Higgins; R Bradley; C A Metz
Journal:  N Engl J Med       Date:  1987-12-17       Impact factor: 91.245

Review 4.  Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Sofie Louise Rygård; Ethan Butler; Anders Granholm; Morten Hylander Møller; Jeremy Cohen; Simon Finfer; Anders Perner; John Myburgh; Balasubramanian Venkatesh; Anthony Delaney
Journal:  Intensive Care Med       Date:  2018-05-14       Impact factor: 17.440

5.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

6.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Authors:  Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

Review 7.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

8.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.

Authors:  Erica J Brenner; Ryan C Ungaro; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Frank M Ruemmele; Flavio Steinwurz; Fox E Underwood; Xian Zhang; Jean-Frederic Colombel; Michael D Kappelman
Journal:  Gastroenterology       Date:  2020-05-18       Impact factor: 22.682

9.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.

Authors:  Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph
Journal:  N Engl J Med       Date:  2020-06-29       Impact factor: 91.245

10.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

View more
  2 in total

Review 1.  Impact of SARS-CoV-2 on Host Factors Involved in Mental Disorders.

Authors:  Raina Rhoades; Sarah Solomon; Christina Johnson; Shaolei Teng
Journal:  Front Microbiol       Date:  2022-04-04       Impact factor: 6.064

2.  Evaluating immunohaematological profile among COVID-19 active infection and recovered patients in Ghana.

Authors:  Yatik Konlaan; Samuel Asamoah Sakyi; Kwame Kumi Asare; Prince Amoah Barnie; Stephen Opoku; Gideon Kwesi Nakotey; Samuel Victor Nuvor; Benjamin Amoani
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.